A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and Merck & Co. The ...

Delhi has long stood as a beacon of modern healthcare. The national capital is home to gleaming hospitals, internationally ...

Roche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been dashed by a late-stage trial failure looking at the drug in combination with ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills ...

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has ...

Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...